PharmaPoint: Type 1 Diabetes Market, Global Drug Forecast and Market Analysis to 2023
Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present, no other treatment can be offered to a patient who is newly diagnosed with T1D. A variety of insulin analogs with different times of action - long-acting as well as short or rapid-acting analogs - have been on the market for the past decade. In addition, many other developments were happening in parallel, such as glucose monitoring and significant advances in insulin delivery systems. The T1D market will approximately double over the forecast period, growing from $6.6 billiion to $13.6 billion.This growth will be fueled by the significant increase in T1D prevalence as well as the uptake of the novel ultra-long-acting insulin analogs, novel ultra-rapid formulations of insulin analogs, and the adjunct therapies for T1D. The launches of these novel products will offset the dip in sales caused by the patent expiries of seven insulin products, and the consequent emergence of biosimilars. Read Complete Report with TOC: http://www.marketresearchstore.com/report/pharmapoint-type-1-diabetes-global-drug-forecast-13811
Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present, no other treatment can be offered to a patient who is newly diagnosed with T1D. A variety of insulin analogs with different times of action - long-acting as well as short or rapid-acting analogs - have been on the market for the past decade. In addition, many other developments were happening in parallel, such as glucose monitoring and significant advances in insulin delivery systems. The T1D market will approximately double over the forecast period, growing from $6.6 billiion to $13.6 billion.This growth will be fueled by the significant increase in T1D prevalence as well as the uptake of the novel ultra-long-acting insulin analogs, novel ultra-rapid formulations of insulin analogs, and the adjunct therapies for T1D. The launches of these novel products will offset the dip in sales caused by the patent expiries of seven insulin products, and the consequent emergence of biosimilars.
Read Complete Report with TOC: http://www.marketresearchstore.com/report/pharmapoint-type-1-diabetes-global-drug-forecast-13811
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Market</strong> Research S<strong>to</strong>re<br />
<strong>PharmaPoint</strong>: <strong>Type</strong> 1<br />
<strong>Diabetes</strong><br />
<strong>Market</strong><br />
Size, Share, <strong>Global</strong> Trends,<br />
<strong>Analysis</strong>, Research Report<br />
<strong>and</strong> <strong>Forecast</strong>,<br />
2015-<strong>2023</strong><br />
www.marketresearchs<strong>to</strong>re.com<br />
sales@marketresearchs<strong>to</strong>re.com
<strong>PharmaPoint</strong>: <strong>Type</strong> 1 <strong>Diabetes</strong> <strong>Market</strong>, <strong>Global</strong> <strong>Drug</strong><br />
<strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong><br />
<strong>Type</strong> 1 diabetes (T1D) is an au<strong>to</strong>immune disease that permanently<br />
destroys beta cells of the pancreatic islet, which means that the body can<br />
no longer produce insulin. Over the last 90 years, insulin therapy has<br />
been evolving continuously, as at present, no other treatment can be<br />
offered <strong>to</strong> a patient who is newly diagnosed with T1D. A variety of insulin<br />
analogs with different times of action - long-acting as well as short or<br />
rapid-acting analogs - have been on the market for the past decade. In<br />
addition, many other developments were happening in parallel, such as<br />
glucose moni<strong>to</strong>ring <strong>and</strong> significant advances in insulin delivery systems.
The T1D market will approximately double over the forecast period,<br />
growing from $6.6 billiion <strong>to</strong> $13.6 billion.This growth will be fueled by<br />
the significant increase in T1D prevalence as well as the uptake of the<br />
novel ultra-long-acting insulin analogs, novel ultra-rapid formulations of<br />
insulin analogs, <strong>and</strong> the adjunct therapies for T1D. The launches of these<br />
novel products will offset the dip in sales caused by the patent expiries of<br />
seven insulin products, <strong>and</strong> the consequent emergence of biosimilars.<br />
Read Complete Report with TOC:<br />
http://www.marketresearchs<strong>to</strong>re.com/report/pharmapoint-type-1-<br />
diabetes-global-drug-forecast-13811
Highlights<br />
Key Questions Answered<br />
‣ Insulin therapy has been the corners<strong>to</strong>ne of the T1D treatment. The<br />
advances in insulin therapies have contributed <strong>to</strong> better treatment of<br />
T1D patients; nevertheless, the overall life expectancy in T1D<br />
patients is still 10-15 years less than in the healthy population.<br />
Therefore, there are considerably high unmet needs within the<br />
indication. What are the main unmet needs in this market? Will the<br />
drugs under development fulfil the unmet needs of the T1D market?<br />
‣ The current late-stage T1D pipeline encompasses one novel ultra-
long-acting insulin analog, several novel ultra-rapid formulations of<br />
already marketed human insulins <strong>and</strong> rapid-insulin analogs,<br />
biosimilar versions of marketed insulins, <strong>and</strong> last but not least,<br />
adjunctive therapies that are focused on complementing intensive<br />
insulin therapy. Will the late-stage drugs make a significant impact<br />
on the T1D market? Which of these drugs will have the highest peak<br />
sales at the highest CAGR, <strong>and</strong> why?<br />
‣ We have seen a significant increase in T1D diagnosed prevalence<br />
over the past 10 years. How will epidemiological changes impact the<br />
growth of the future market?<br />
Key Findings
‣ The main driver of the enormous expansion of the T1D market<br />
will be the significant increase in T1D diagnosed prevalence as<br />
well as the uptake of novel ultra-long-acting insulin analogs ,<br />
novel ultra-rapid-acting formulations of currently marketed<br />
rapid-acting insulin analogs <strong>and</strong> adjunct therapies such as GLP-<br />
1 RAs <strong>and</strong> SGLT-2, inhibi<strong>to</strong>rs.<br />
‣ The major global barrier for the T1Dmarket will be the<br />
biosimilar erosion of the leading insulin br<strong>and</strong>s for T1D<br />
treatment, such as Lantus (insulin glargine), Levemir (insulin<br />
detemir), Humalog (insulin lispro), <strong>and</strong> NovoLog (insulin<br />
aspart).
‣ The dynamics of the insulin market will not change drastically<br />
over the next 10 years in terms of the current <strong>and</strong> future<br />
players in the T1D market <strong>and</strong> <strong>Global</strong>Data expects that Novo<br />
Nordisk, Sanofi, <strong>and</strong> Eli Lilly will continue ruling this space, as<br />
they are undertaking various strategies <strong>to</strong> defend their<br />
franchises from upcoming biosimilar erosion.<br />
‣ One of the largest unmet needs is a need for therapies that<br />
would interfere with the pathogenic processes involved in the<br />
eradication of the beta cells in T1D patients. Other unmet<br />
needs include hypoglycemia avoidance, weight loss <strong>and</strong> control<br />
of the associated metabolic syndrome, treatment for brittle<br />
diabetes, <strong>and</strong> increased patient compliance.
Read Complete Report with TOC:<br />
http://www.marketresearchs<strong>to</strong>re.com/report/pharmapoint-type-1-<br />
diabetes-global-drug-forecast-13811<br />
Scope<br />
‣ Overview of type 1 diabetes, including epidemiology, etiology,<br />
pathophysiology, symp<strong>to</strong>ms, diagnosis, <strong>and</strong> treatment<br />
guidelines.<br />
‣ Annualized T1D therapeutics market revenue, annual cost of<br />
therapy <strong>and</strong> treatment usage pattern data from 2013 <strong>and</strong>
forecast for ten years <strong>to</strong> <strong>2023</strong>.<br />
‣ Key <strong>to</strong>pics covered include strategic competi<strong>to</strong>r assessment,<br />
market characterization, unmet needs, clinical trial mapping<br />
<strong>and</strong> implications for the T1D therapeutics market.<br />
‣ Pipeline analysis: comprehensive data split across different<br />
phases, emerging novel trends under development, <strong>and</strong><br />
detailed analysis of late-stage pipeline drugs.<br />
‣ <strong>Analysis</strong> of the current <strong>and</strong> future market competition in the<br />
global T1Dtherapeutics market. Insightful review of the key<br />
industry drivers, restraints <strong>and</strong> challenges. Each trend is<br />
independently researched <strong>to</strong> provide qualitative analysis of its<br />
implications.
Reasons <strong>to</strong> buy<br />
‣ Develop <strong>and</strong> design your in-licensing <strong>and</strong> out-licensing<br />
strategies through a review of pipeline products <strong>and</strong><br />
technologies, <strong>and</strong> by identifying the companies with the most<br />
robust pipeline.<br />
‣ Additionally a list of acquisition targets included in the pipeline<br />
product company list.<br />
‣ Develop business strategies by underst<strong>and</strong>ing the trends<br />
shaping <strong>and</strong> driving the global T1D therapeutics market.<br />
‣ Drive revenues by underst<strong>and</strong>ing the key trends, innovative
products <strong>and</strong> technologies, market segments, <strong>and</strong> companies<br />
likely <strong>to</strong> impact the global T1D therapeutics market in future.<br />
‣ Formulate effective sales <strong>and</strong> marketing strategies by<br />
underst<strong>and</strong>ing the competitive l<strong>and</strong>scape <strong>and</strong> by analysing the<br />
performance of various competi<strong>to</strong>rs.<br />
‣ Identify emerging players with potentially strong product<br />
portfolios <strong>and</strong> create effective counter-strategies <strong>to</strong> gain a<br />
competitive advantage.<br />
‣ Track drug sales in the global T1D therapeutics market from<br />
2013-<strong>2023</strong>.<br />
‣ Organize your sales <strong>and</strong> marketing efforts by identifying the<br />
market categories <strong>and</strong> segments that present maximum
opportunities for consolidations, investments <strong>and</strong> strategic<br />
partnerships.<br />
Get Sample Copy of Report:<br />
http://www.marketresearchs<strong>to</strong>re.com/report/pharmapoint-type-1-<br />
diabetes-global-drug-forecast-13811#requestSample<br />
1 Table of Contents<br />
1 Table of Contents 11<br />
1.1 List of Tables 16<br />
1.2 List of Figures 21<br />
2 Introduction 22
2.1 Catalyst 22<br />
2.2 Related Reports 23<br />
2.3 Upcoming Related Reports 23<br />
3 Disease Overview 24<br />
3.1 Etiology <strong>and</strong> Pathophysiology 24<br />
3.1.1 Etiology 24<br />
3.1.2 Pathophysiology 26<br />
3.1.3 Biomarkers for Moni<strong>to</strong>ring the Islet Au<strong>to</strong>reactivity of <strong>Type</strong> 1<br />
<strong>Diabetes</strong> 27<br />
3.2 Symp<strong>to</strong>ms 28<br />
3.3 Prognosis 29<br />
3.4 Quality of Life 29
4 Epidemiology 31<br />
4.1 Disease Background 31<br />
4.2 Risk Fac<strong>to</strong>rs <strong>and</strong> Comorbidities 32<br />
4.3 <strong>Global</strong> Trends 34<br />
4.3.1 US 34<br />
4.3.2 5EU 35<br />
4.3.3 Japan 35<br />
4.3.4 Canada 36<br />
Read More: http://www.marketresearchs<strong>to</strong>re.com/report/pharmapointtype-1-diabetes-global-drug-forecast-13811
About Us<br />
<strong>Market</strong> Research S<strong>to</strong>re is a single destination for all the industry,<br />
company <strong>and</strong> country reports. We feature large reposi<strong>to</strong>ry of latest<br />
industry reports, leading <strong>and</strong> niche company profiles, <strong>and</strong> market<br />
statistics released by reputed private publishers <strong>and</strong> public<br />
organizations.<br />
Contact Us<br />
TELEPHONE: +1-386-310-3803 Us:Stay<br />
With<br />
E-MAIL:<br />
sales@marketresearchs<strong>to</strong>re.com<br />
Suite #8138, 3422 SW<br />
15 Street,<br />
Deerfield Beach, Florida<br />
33442<br />
United States
Change language